Tumor Necrosis Factor Inhibitor Therapy in Polyarteritis Nodosa: Expanding Evidence From Systemic to Cutaneous Disease
We read with great interest the recent article by Dr. Harama et al published in <i>The Journal of Rheumatology</i> regarding the off-label use of tumor necrosis factor inhibitors (TNFi) in the management of cutaneous polyarteritis nodosa (PAN)-associated refractory leg ulcers.<sup>1</sup> The authors present compelling evidence supporting the therapeutic efficacy of this drug class in a clinical indication not currently supported by established treatment guidelines.
Authors
- Itzhak Rosner (ORCID: https://orcid.org/0000-0002-1370-8708)
- Shira Ginsberg (ORCID: https://orcid.org/0000-0002-5891-4484)
Institutions
- Technion – Israel Institute of Technology (IL)
- Bnai Zion Medical Center (IL)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2025-11-15
- DOI
- https://doi.org/10.3899/jrheum.2025-0741
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00